Understanding the Market Window for Sacubitril Valsartan Sodium Related Intermediates Sacubitril Valsartan Sodium, known by its development code LCZ696 and brand name Entresto, is an angiotensin receptor neprilysin inhibitor (ARNI) widely studied for cardiovascular research. For R&D teams, fine chemical developers and CDMO institutions working in this research field, project timing carries great importance: the core US patent expired in July 2023, and the relevant compound patent in China is scheduled to expire in 2026.
This has created what industry participants refer to as a “golden window” ahead of accelerated development activities. During this phase, many research and development organizations are seeking qualified, stable and cost-effective Sacubitril Calcium intermediates to support synthetic route exploration, internal regulatory preparation and pre-project material reserve planning.
In this context, selecting a reliable supplier for Sacubitril Valsartan-related synthetic materials carries substantial implications. Buyers seek partners capable of delivering consistent material quality, traceable technical documentation and mature technical support across the whole synthetic sequence — from starting materials to advanced co-crystal precursors.
Why Full-Chain Intermediate Supply Matters
Shandong Tianming Pharmaceutical Group, operating under the brand Tianming Pharmaceutical, has developed its Sacubitril Valsartan-related intermediate series around this full-chain development logic. The portfolio covers sequential synthetic materials along the synthetic pathway, including starting materials and advanced intermediates for the co-crystal route. This lineup is designed for synthetic development, rather than focusing on finished drug substances.
This setup brings practical value to development teams, as projects often require material supply that can transition smoothly from lab-scale trials to pilot batches and larger bulk runs. Switching suppliers mid-process often introduces extra quality risks and timeline delays. The intermediate catalog includes:
- Sacubitril Valsartan Sodium co-crystal intermediate (CAS 936623-90-4): advanced co-crystal precursor for synthetic route research
- Sacubitril Calcium (CAS 136977-33-9): key advanced intermediate applicable to Sacubitril Valsartan Sodium co-crystal synthesis research and independent new compound route exploration, such as Sacubitril Alisartan Calcium research
- Chiral starting material (CAS 142612-95-0-1): chiral raw material for Sacubitril synthesis
- Ethoxycarbonylmethylene triphenylphosphorane (CAS 5717-37-3): Wittig reagent used in olefination reaction steps
- Unsaturated coupling intermediate (CAS 101234-14-8-8): intermediate obtained after Wittig coupling reaction
- Saturated chiral intermediate (CAS 101234-15-0-2): chiral intermediate produced after hydrogenation
- Deprotected chiral amine intermediate (CAS 149690-12-0): deprotected chiral amine building block
With this full sequence of intermediates available from one supplier, buyers can reduce the coordination overhead and quality alignment risks that come with managing multiple vendors for a single synthetic route.
Quality Control for Research-Grade Intermediates
Consistent batch performance is a non-negotiable requirement for teams working on multi-step chiral synthesis. Tianming Pharmaceutical applies standardized internal quality control protocols for this intermediate series, with tight monitoring of molar ratio parameters for co-crystal research, chiral impurities, residual solvents, particle characteristics and crystal form. For Sacubitril Calcium, typical specifications include individual single impurity below 0.1% and chiral purity above 99.5%.
All batches are supplied with supporting technical records including COA, analytical test protocols, impurity profile datasets and stability study records. Buyers may reference these materials when compiling their own dossiers for regulatory preparation. This complete technical package helps R&D teams streamline their internal qualification workflows.
Scale, Capacity and Process Development Capability
The product portfolio is backed by flexible production infrastructure to support both pilot and bulk intermediate batches. Tianming Pharmaceutical Group operates three production bases with over 160 reactor vessels in total, delivering intermediate output capacity at the hundred-ton scale annually. For the Sacubitril Valsartan intermediate series, the team supports flexible supply ranging from gram-scale R&D samples up to commercial bulk batches.
The in-house technical team carries out process route optimization tailored for scale-up, with batch consistency built into process design rather than only relying on final testing. Analytical verification is supported by HPLC, GC, mass spectrometry, LC-MS and chiral analysis instruments, which are essential for monitoring complex multi-component chiral intermediates.
Positioning Within the Broader Intermediate Portfolio
The Sacubitril Valsartan intermediate series is one of the group’s flagship product families, alongside the full-chain intermediate portfolio for Orforglipron under the GLP-1 research category. The group is an R&D-focused supplier of pharmaceutical raw materials and synthetic intermediates with an integrated R&D-production model, offering custom CMO/CDMO synthesis and process development services for global R&D partners.
This capability is supported by two R&D centers in Jinan and Nanjing, with more than 6,000 square meters of laboratory space, an R&D team of over 100 specialists, and annual R&D investment exceeding 10% of revenue. Digital management systems including CRM, ERP and BPM are deployed to streamline order tracking, inventory planning and production scheduling, supporting cross-border logistics coordination for overseas buyers.
Core Considerations for Intermediate Sourcing
R&D teams exploring cardiovascular synthetic routes, CDMO partners undertaking custom synthesis projects, and chemical developers preparing for upcoming patent expiry timelines all share a common question when evaluating suppliers of Sacubitril Valsartan-related materials: can one technical partner support the full range of material supply and technical service required, from initial sampling through scaled-up batches, while maintaining strict impurity control and complete traceable documentation?
Tianming Pharmaceutical Group’s integrated intermediate matrix, standardized internal quality specifications, scalable reactor capacity and comprehensive technical documentation framework address this demand for the Sacubitril Valsartan research route. As the 2026 China patent expiry draws near, development teams have a window to evaluate whether consolidated full-chain intermediate sourcing can fit their internal regulatory preparation and project rollout schedules. Both catalog intermediate sales and custom CMO/CDMO synthesis services are available, covering gram to ton scale, allowing buyers to adjust supply volumes as their projects advance without switching suppliers.
Disclaimer
All products listed are fine chemical intermediates and synthetic building blocks, supplied exclusively for laboratory research, synthetic route exploration and process development. They are not finished drug substances and are not intended for direct clinical use. Compound names and CAS numbers are provided solely for chemical identification. Purchasers shall independently conduct FTO patent freedom assessment and comply with local regulatory rules before any commercial application.
Tianming Pharmaceutical Group
